Purpose of dual packaging in photostability testing:

Photostability testing involves exposing pharmaceutical products to light to evaluate their stability under light stress conditions. ICH Q1B recommends storing samples in both light-transmitting (transparent) and light-protective (e.g., foil-wrapped or amber) containers during testing to differentiate between light-induced and non-light-induced changes.

This setup ensures that any observed degradation is truly due to light exposure and not other environmental factors.

Consequences of using a single packaging format:

Testing with only light-protective packaging may obscure degradant formation, while using only transparent packaging may overestimate degradation. Without a comparative analysis, it is impossible to establish whether degradation is specifically light-induced or due to unrelated environmental effects like heat or oxygen.

Scientific and regulatory benefits of this approach:

Using both packaging types helps identify critical photolabile components, supports protective packaging decisions, and validates labeling claims such as “Protect from light.” It also ensures test compliance with ICH and supports accurate shelf-life assessments.

Regulatory and Technical Context:

ICH Q1B photostability test design:

ICH Q1B requires that photostability studies expose samples to a combination of UV and visible light totaling at least 1.2 million lux hours and 200 watt-hours/m² of UV energy. Samples must be split into two sets: one exposed directly and another protected from light (as a control).

This allows for a direct comparison between light-exposed and protected samples to determine the specific impact of light on product degradation.

Audit and CTD submission implications:

Regulators reviewing Module 3.2.P.8.3 of the CTD expect evidence that photostability samples were appropriately handled. Absence of a protective packaging control set—or unclear documentation of sample storage conditions—may result in data rejection or follow-up questions during inspection.

Photostability packaging setup is also inspected during GMP site visits to verify test integrity and method execution accuracy.

Best Practices and Implementation:

Select packaging materials that reflect real-world exposure:

Use clear containers (e.g., colorless glass or plastic) for transparent sample storage and mimic commercial packaging conditions. For the protected set, use foil overwraps, amber glass, or custom-designed light-protective barriers validated to block both UV and visible wavelengths.

Document the spectral transmission properties of both packaging types as part of your photostability protocol.

Include both packaging types in protocol and labels:

Photostability protocols should clearly specify the use of both packaging types, define placement within the photostability chamber, and identify the orientation and exposure surface. Assign unique sample IDs to track transparent and protective units throughout the study.

In final reports, describe any observed differences in degradation to justify packaging selection or labeling decisions.

Use results to guide product design and regulatory claims:

If transparent packaging shows significant degradation while the protected set does not, consider using protective packaging in the final commercial presentation. Justify label statements like “Store in original packaging” or “Protect from light” using these comparative findings.

Train QA and analytical teams on interpreting photostability results and linking degradation to container type for improved risk management and inspection readiness.